646 related articles for article (PubMed ID: 30218025)
1. Mechanisms, biomarkers and targets for adult-onset Still's disease.
Feist E; Mitrovic S; Fautrel B
Nat Rev Rheumatol; 2018 Oct; 14(10):603-618. PubMed ID: 30218025
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review on adult onset Still's disease.
Giacomelli R; Ruscitti P; Shoenfeld Y
J Autoimmun; 2018 Sep; 93():24-36. PubMed ID: 30077425
[TBL] [Abstract][Full Text] [Related]
3. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
[TBL] [Abstract][Full Text] [Related]
4. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
[TBL] [Abstract][Full Text] [Related]
5. [Adult-onset Still's disease : Rare adult-onset autoinflammatory syndrome].
Oms E; Tronnier M
Hautarzt; 2019 Jul; 70(7):530-534. PubMed ID: 30937478
[TBL] [Abstract][Full Text] [Related]
6. Adult-onset Still's disease.
Gerfaud-Valentin M; Jamilloux Y; Iwaz J; Sève P
Autoimmun Rev; 2014 Jul; 13(7):708-22. PubMed ID: 24657513
[TBL] [Abstract][Full Text] [Related]
7. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
8. Circulating Neutrophil Extracellular Traps Signature for Identifying Organ Involvement and Response to Glucocorticoid in Adult-Onset Still's Disease: A Machine Learning Study.
Jia J; Wang M; Ma Y; Teng J; Shi H; Liu H; Sun Y; Su Y; Meng J; Chi H; Chen X; Cheng X; Ye J; Liu T; Wang Z; Wan L; Zhou Z; Wang F; Yang C; Hu Q
Front Immunol; 2020; 11():563335. PubMed ID: 33240258
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.
Wang MY; Jia JC; Yang CD; Hu QY
Chin Med J (Engl); 2019 Dec; 132(23):2856-2864. PubMed ID: 31856058
[TBL] [Abstract][Full Text] [Related]
10. Biologics for the treatment of adult-onset still's disease.
Yoo DH
Expert Opin Biol Ther; 2019 Nov; 19(11):1173-1190. PubMed ID: 31379214
[No Abstract] [Full Text] [Related]
11. The implication of interferon-γ-producing immunocompetent cells for evaluating disease activity and severity in adult-onset Still's disease.
Ichikawa T; Shimojima Y; Kishida D; Ueno KI; Sekijima Y
Int J Rheum Dis; 2021 Sep; 24(9):1176-1185. PubMed ID: 34241971
[TBL] [Abstract][Full Text] [Related]
12. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of adult onset still's disease: current understanding and new insights.
Ruscitti P; Giacomelli R
Expert Rev Clin Immunol; 2018 Nov; 14(11):965-976. PubMed ID: 30295095
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis.
Hu Q; Gong W; Gu J; Geng G; Li T; Tian R; Yang Z; Zhang H; Shao L; Liu T; Wan L; Jia J; Yang C; Shi Y; Shi H
Front Immunol; 2018; 9():3099. PubMed ID: 30687316
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and management of adult-onset Still's disease.
Efthimiou P; Georgy S
Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
[TBL] [Abstract][Full Text] [Related]
16. Hemophagocytic syndrome in adult-onset Still's disease (AOSD): a must for biologics?--Case report and brief review of the literature.
Bürgi U; Mendez A; Hasler P; Hüllstrung HD
Rheumatol Int; 2012 Oct; 32(10):3269-72. PubMed ID: 20383508
[TBL] [Abstract][Full Text] [Related]
17. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C; Fautrel B; Rech J; Spertini F; Feist E; Kötter I; Hachulla E; Morel J; Schaeverbeke T; Hamidou MA; Martin T; Hellmich B; Lamprecht P; Schulze-Koops H; Courvoisier DS; Sleight A; Schiffrin EJ
Ann Rheum Dis; 2018 Jun; 77(6):840-847. PubMed ID: 29472362
[TBL] [Abstract][Full Text] [Related]
18. [Adult-onset Still's disease].
Dechant C; Krüger K
Dtsch Med Wochenschr; 2011 Aug; 136(33):1669-73. PubMed ID: 21833888
[TBL] [Abstract][Full Text] [Related]
19. Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.
Li S; Zheng S; Tang S; Pan Y; Zhang S; Fang H; Qiao J
Clin Rev Allergy Immunol; 2020 Feb; 58(1):71-81. PubMed ID: 31147820
[TBL] [Abstract][Full Text] [Related]
20. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
